CRVS
Corvus Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
14.80
▲ 0.47 (3.28%)
MARKET · —
Price
Open
13.00
Prev close
14.33
Day high
14.76
Day low
14.38
Volume
461.29K
Market cap
$1.22B
P/E (TTM)
—
52W range
5.28 – 26.95
Trailing performance
Returnvs SPY
1W
-2.89%
-1.5%
1M
+5.70%
+2.0%
3M
+10.55%
+7.5%
6M
-12.73%
-23.8%
YTD
+87.79%
+75.5%
1Y
+178.61%
+158.6%
3Y
+595.19%
+521.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.22B
Enterprise value$1.00B
Revenue (TTM)—
Gross profit—
EBITDA$-56.85M
Net income$-54.13M
EPS (TTM)$-0.64
Free cash flow$-27.40M
Total cash$215.23M
Total debt$728.00K
Book value / share$2.68
Shares outstanding84.12M
Float72.79M
Short % of float24.74%
Dividend yield—
Beta (5Y)0.87
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.55
PEG ratio—
Price / sales—
Price / book5.40
EV / revenue—
EV / EBITDA-17.63
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-35.43%
Return on assets-21.66%
Debt / equity0.32
Current ratio16.16
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.17 | -0.19 | -13.4% |
| Mar 2026 | -0.15 | -0.15 | +2.2% |
| Dec 2025 | -0.13 | -0.15 | -13.2% |
| Sep 2025 | -0.14 | -0.12 | +11.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 4 | $0 | 0.0% |
| Next quarter | -0.23 | 4 | $0 | 0.0% |
| Current year | -0.78 | 4 | $0 | 0.0% |
| Next year | -1.07 | 4 | $4.55M | 0.0% |
Analyst targets & ownership
Mean target$33.14
High target$42.00
Low target$27.00
Implied upside123.94%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders3.51%
Held by institutions86.09%
Institutions holding236
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.95M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 26 | MOORE DAVID SCOTT Director |
BUY | 21.70K | $250.24K | Direct |
| May 18, 26 | MILLER RICHARD A Chief Executive Officer |
BUY | 6.93K | $83.45K | Indirect |
| Jun 27, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.40M | $4.89M | Indirect |
| Jun 27, 25 | THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.40M | $4.89M | Indirect |
| Jun 27, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.18M | $4.89M | Indirect |
| Jun 27, 25 | THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.18M | $4.89M | Indirect |
| Jun 4, 25 | JONES WILLIAM BENTON Officer |
CONVERSION | 19.36K | $67.75K | Direct |
| May 7, 25 | MILLER RICHARD A Chief Executive Officer |
CONVERSION | 559.07K | $1.96M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
JONES WILLIAM BENTON |
Officer | 173.13K | Conversion of Exercise of derivative security |
MILLER RICHARD A |
Chief Executive Officer | — | Purchase |
MOORE DAVID SCOTT |
Director | 21.70K | Purchase |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
THOMPSON PETER A |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
14.75
+0.35% from price
SMA 20
14.11
+2.48% from price
SMA 50
13.98
+3.40% from price
SMA 100
14.09
+5.03% from price
SMA 200
13.48
+7.25% from price
EMA 12
14.56
+1.63% from price
EMA 26
14.32
+3.36% from price
EMA 50
14.13
+4.71% from price
RSI (14)
51.8
Neutral
MACD (12,26,9)
0.24
Hist 0.04
ATR (14)
0.75
5.17% of price
Realised vol 30D
51.2%
Annualised
Bollinger upper
15.63
20, 2σ
Bollinger lower
12.59
20, 2σ
50 / 200 cross
Golden
13.98 vs 13.48
Trend bias
Above 200
+7.25%
Risk profile
Beta vs SPY
-0.48
Less volatile than market
Correlation to SPY
-0.03
Largely independent
Realised vol 30D
51.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-56.4%
Peak to trough
Max drawdown 5Y
-92.4%
Peak to trough
ATR 14
0.75
5.17% of price
Beta (reported)
0.87
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.34
Call-heavy session
Put / call open interest
0.25
Positioning, not flow
Max pain
15.00
+3.7% from spot
ATM implied vol
131.8%
Nearest strike to spot
Skew (10% OTM)
+8.4%
Puts bid over calls
Call volume
82
Contracts, this expiry
Put volume
28
Contracts, this expiry
Heaviest call OI
16.00
1.05K contracts
Heaviest put OI
11.00
102 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
Insider Monkey · 5d ago
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
Motley Fool · 8d ago
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
GuruFocus.com · 16d ago
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 16d ago
Corvus Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 16d ago
Corvus: Q2 Earnings Snapshot
Associated Press · 16d ago
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
GlobeNewswire · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.